BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

Executive Summary

• BioSyent reported a 23% increase in net income after tax to $9.01 M for FY 2025, with total company sales up 23% to $43.05 M year‑over‑year.
• EBITDA rose 30% to $12.12 M and fully diluted EPS increased 27% to $0.78 for the full year.
• The company completed the acquisition of Oral Science Inc., repurchased 19,500 shares under its NCIB, and raised its quarterly dividend by 10% to $0.055 per share.

Key Details

• Revenue Highlights – Canadian pharma sales: $8.79 M Q4 (+3% YoY); International pharma sales: $0.60 M Q4 (+240% YoY); Legacy business sales: $0.28 M Q4 (+278% YoY). FY 2025 total sales $43.05 M (+23% YoY).
• Profitability – EBITDA FY 2025: $12.12 M (+30% YoY); Net income after tax FY 2025: $9.01 M (+24% YoY); Fully diluted EPS FY 2025: $0.78 (+27%).
• Return on Equity – 24% for FY 2025 vs. 21% in FY 2024.
• Share Repurchase – 19,500 common shares repurchased and cancelled under the Normal Course Issuer Bid (NCIB).
• Dividends – Quarterly cash dividends of $0.05 per share paid Q1–Q4 2025; dividend increased 10% to $0.055 per share for March 13 2026 payment.
• Acquisition – Completed acquisition of Oral Science Inc., a Canadian dental hygiene and oral health products distributor (announced March 2 2026).
• International Tibelia® Sales – Generated $2.4 M in 2025 from the Tibelia® (tibolone) assets acquired in 2024.
• Balance Sheet Highlights – Cash & equivalents rose 80% to $28.65 M; total assets increased 20% to $49.44 M; equity up 18% to $41.47 M.
• Operating Metrics – Cost of goods sold grew 36% Q4 YoY, 41% FY YoY; operating expenses rose modestly (1% Q4, 16% FY).

Notable Quotes

“We finished 2025 with double‑digit overall revenue growth… We will continue to invest in growth and product diversification while returning capital to shareholders through share buybacks and regular cash dividends.” – René Goehrum, President & CEO

Materiality Assessment: Material – Positive (significant earnings improvement, dividend increase, acquisition, and strong balance‑sheet enhancements).